FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy

CMO rises from biotech's ashes

Tools

Introgen Therapeutics, which filed for bankruptcy protection late last year, is getting a second shot at life, of sorts.

Houston investors have purchased the company's manufacturing-related assets, reports the Houston Business Journal, and from them formed contract manufacturer Vivante GMP Solutions. At bankruptcy, the Introgen assets were divided into three: manufacturing patents, therapeutic drug assets, and manufacturing-related assets. The investors took advantage of the latter, which include a facility and documentation required to manufacture third-party biologic drugs and clinical trials.

Vivante's focus is biologics for academic institutions and biotech companies. According to the press report, several biotechs have engaged the CMO, and it retained customers throughout the bankruptcy, as an Introgen subsidiary.

- see the article

Related Articles:
Bankrupt Introgen operations revived as CMO
Introgen files for Chapter 11, marketing drug portfolio
Small biotechs outline harsh spending cuts
Introgen 'explores options' after troubled Q3
Introgen shares plunge on BLA rejection


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:
Comments (1) | Post a comment
More stories about CMO   Bankruptcy Protection   Contract Manufacturer   Introgen  

Comments

You've got to be kidding! There are still investers foolish enough to put their moneny into a new biologic CMO? Obviously they aren't aware that 99.9% of clinical CMOs have never made a dime (but have lost millions and millions in monthly operating costs).

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.